ProQR Therapeutics N.V. (NASDAQ:PRQR)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $3.63 and last traded at $3.63, with a volume of 66659 shares trading hands. The stock had previously closed at $3.70.

A number of equities analysts have recently issued reports on PRQR shares. Zacks Investment Research upgraded shares of ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Tuesday, August 22nd. ValuEngine upgraded shares of ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Chardan Capital reiterated a “neutral” rating on shares of ProQR Therapeutics N.V. in a report on Sunday, September 17th. JMP Securities increased their price target on shares of ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, September 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. ProQR Therapeutics N.V. currently has an average rating of “Hold” and an average price target of $19.38.

The company has a quick ratio of 8.22, a current ratio of 8.22 and a debt-to-equity ratio of 0.17.

Large investors have recently bought and sold shares of the business. Nine Chapters Capital Management LLC purchased a new position in ProQR Therapeutics N.V. during the 3rd quarter valued at about $133,000. Janus Henderson Group PLC purchased a new position in ProQR Therapeutics N.V. during the 2nd quarter valued at about $2,028,000. Artal Group S.A. increased its holdings in ProQR Therapeutics N.V. by 25.0% during the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in ProQR Therapeutics N.V. by 2.8% during the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after acquiring an additional 43,050 shares in the last quarter. Hedge funds and other institutional investors own 36.04% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/08/proqr-therapeutics-n-v-prqr-reaches-new-1-year-low-at-3-63.html.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Receive News & Stock Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related stocks with our FREE daily email newsletter.